Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Are US pharma companies immune to US–Canada trade wars?
  2. Deals and M&As this week: Alliance Pharma, Bayer, Onxeo
  3. Merck to distribute HistoCyte Laboratories’ cell line products
  4. Researchers identify brain metals that may precipitate Alzheimer’s
  5. Regenerative therapy for peripheral artery disease moves forward

Latest Content

Security of Pharmaceuticals – Comparing US and EU Standards

What do the Falsified Medicine Directive (FMD) and the Drug Supply Chain Security Act (DSCSA) in common and what are their differences? This white paper presents the main provisions of both legal frameworks and assists in developing a deeper understanding of the requirements for pharmaceutical companies.

Regenerative therapy for peripheral artery disease moves forward

Encouraging Phase II results were released last week for Pluristem’s PLX-PAD, a placenta-based allogeneic stem cell therapy given intramuscularly, targeting peripheral artery disease (PAD). The positive results are great news for patients who suffer from PAD, a circulatory problem in which narrowed arteries reduce blood flow to the limbs, which has limited treatment options available.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top